Completed PHASE2 INTERVENTIONAL 3-arm NCT00207714

An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate

Sponsor: Centocor BV

Conditions Rheumatoid Arthritis

Interventions Golimumab Infliximab MTX Placebo

Updated 6 times since 2017 Last updated: Oct 16, 2012 Started: Nov 30, 2003 Primary completion: Feb 28, 2005 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Centocor BV leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centocor BV
Centocor, Inc.

Data source: Centocor, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.